Who is sponsoring NCT00744809?

NCT00744809 is sponsored by Tibotec Pharmaceuticals, Ireland.

What condition does NCT00744809 study?

NCT00744809 studies Human Volunteers.

What drugs are being tested in NCT00744809?

Interventions: TMC278; Moxifloxacin; Efavirenz.

What is the status of NCT00744809?

NCT00744809 is currently COMPLETED.

Last reviewed 2011-06-08 · How we verify

A Phase I, Double-blind, Double-dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-state and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-state on the QT/QTc Interval, in 2 Randomized Panels of Healthy Volunteers

NCT00744809 Phase 1 COMPLETED

This is a study to evaluate the effect of TMC278 25 mg daily on the QT/QTc interval (heart conduction and heart rhythm) in healthy volunteers. In a separate panel of healthy volunteers, the effect of efavirenz (EFV) 600 mg daily on the QT/QTc interval will be evaluated.

Details

Lead sponsor	Tibotec Pharmaceuticals, Ireland
Phase	Phase 1
Status	COMPLETED
Enrolment	120
Start date	2008-08
Completion	2009-01

Conditions

Human Volunteers

Interventions

TMC278; Moxifloxacin; Efavirenz

Primary outcomes

To evaluate the effect of TMC278 25 mg daily at steady state on the QT/QTc interval in healthy volunteers.